Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

18.14 USD +0.18 (+1.00%)
Official Closing Price Updated: 5:39 PM EST, Dec 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Coherus Bio

Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum
From GlobeNewswire News Releases
Coherus BioSciences Announces New Employment Inducement Grants
From GlobeNewswire News Releases
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemother
From GlobeNewswire News Releases
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemother
From GlobeNewswire News Releases
Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
- Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma - 
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
Toripalimab plus standard chemotherapy demonstrates improvement in PFS in first-line advanced nasopharyngeal carcinoma 
From GlobeNewswire News Releases
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
From GlobeNewswire News Releases
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
From GlobeNewswire News Releases
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From GlobeNewswire News Releases
Coherus BioSciences Announces Upcoming Medical Conference Presentations
From GlobeNewswire News Releases
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
From GlobeNewswire News Releases
Coherus BioSciences Announces New Employment Inducement Grants
From GlobeNewswire News Releases
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Ce
From GlobeNewswire News Releases
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Ce
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA 
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA– 
From GlobeNewswire News Releases
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
From GlobeNewswire News Releases
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th
From GlobeNewswire News Releases
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - 
From GlobeNewswire News Releases
Coherus BioSciences Announces New Employment Inducement Grants
From GlobeNewswire News Releases
Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights
– Virtual investor event to take place on Monday, June 7, 2021 at 6 p.m. ET – 
From GlobeNewswire News Releases
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyn
From GlobeNewswire News Releases
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyn
From GlobeNewswire News Releases
Coherus BioSciences to Present at the Bank of America Health Care Conference
From GlobeNewswire News Releases
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
From GlobeNewswire News Releases
Coherus BioSciences Announces New Employment Inducement Grants
From GlobeNewswire News Releases
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
- Toripalimab data will also be featured in ASCO’s official press program - 
From GlobeNewswire News Releases
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting
- Toripalimab data will also be featured in ASCO’s official press program - 
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.